Alzheimer's Archives

In Depth 9 Nov 2023

Blood tests for Alzheimer’s: a hit or a miss?

Doctor’s typically diagnose Alzheimer’s with the help of brain imaging and cognitive tests, along with taking a patient’s medical history into account. But lately, blood tests are gaining recognition for its ability to rule out other potential causes of memory loss, and to diagnose Alzheimer’s more quickly. With American healthcare company Labcorp launching its trio […]

November 9, 2023 - 10 minutesmins - By Roohi Mariam Peter

In Depth 26 Oct 2023

Behind closed doors: The unseen controversies and scandals in Alzheimer’s drug trials

Alzheimer’s disease is the most common form of dementia – which currently affects more than 55 million people globally – making up 60% to 70% of cases. It is a complex disease, encompassing multiple interrelated and progressive destructive processes in the brain, resulting in neuron damage that extends to parts of the brain that enable […]

October 26, 2023 - 11 minutesmins - By Willow Shah-Neville

News and Trends 28 Jul 2023

Could a natural sweetener from hydrangeas treat Alzheimer’s disease?

Amyloid β (Aβ) aggregation is primarily responsible for the development of Alzheimer’s disease (AD). In a new mouse model study, South Korean researchers investigated the effect of phyllodulcin — a natural sweetener found in the hydrangea plant — in inhibiting Aβ accumulation. The results suggest that phyllodulcin effectively inhibits Aβ accumulation and decomposes the pre-aggregated […]

July 28, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 17 Jul 2023

Hope for Alzheimer’s patients after Lilly drug results

Eli Lilly and Company has presented full results from its phase 3 TRAILBLAZER-ALZ 2 study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease (AD). The data were shared at the 2023 Alzheimer’s Association International Conference (AAIC) as a featured symposium and simultaneously published in the Journal of […]

July 17, 2023 - 6 minutesmins - By Jim Cornall

News and Trends 13 Jul 2023

Partnership to progress neurodegenerative disorder treatments

IRBM, Rainwater Charitable Foundation (RCF, Fort Worth, Texas), a private family foundation, and Weill Cornell Medicine (based in New York) are starting a multi-year drug discovery collaboration to identify small molecule cGAS (cyclic GMP-AMP synthase) inhibitors for the treatment of tauopathies and other neurodegenerative diseases. The collaboration brings together IRBM’s capabilities in drug discovery and […]

July 13, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 7 Jul 2023

FDA approves Alzheimer’s treatment

Eisai Co., Ltd. and Biogen Inc. have announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) supporting the traditional approval of LEQEMBI (lecanemab-irmb) 100 mg/mL injection for intravenous use. The decision makes LEQEMBI the first and only approved treatment shown to reduce the rate of disease progression […]

July 7, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 23 Jun 2023

SandboxAQ launches new division to boost drug development

After several years of stealth development, SandboxAQ has announced its bio-pharma molecular simulation division, AQBioSim, and some of its customers. The division is helping bio-pharma and research institutions achieve breakthroughs in treatments for cancer, Alzheimer’s, Parkinson’s, and other conditions. The company is currently working with biopharma companies and university research labs, including AstraZeneca, Sanofi and […]

June 23, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 22 Jun 2023

Alchemab Therapeutics unveils Alzheimer’s candidate

Alchemab Therapeutics, an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, has unveiled data on ATLX-1088, its newly-discovered preclinical Alzheimer’s candidate, at the Antibody Industrial Symposium in Tours, France. ATLX-1088 is a potential first-in-class human antibody targeting CD33, a cell surface protein thought to have a key role in Alzheimer’s disease. […]

June 22, 2023 - 3 minutesmins - By Jim Cornall

induced pluripotent stem cells ipsc Alzheimer's

News and Trends 13 Jun 2023

‘Clinical trial in a dish’ for Alzheimer’s disease

Axol Bioscience Ltd., a pluripotent stem cell technology provider for drug discovery, has signed an agreement with StrataStem to access and commercialize its collection of Alzheimer’s disease (AD) patient samples. Harnessing its stem cell knowledge, Axol will reprogram these patient samples into induced pluripotent stem cells (iPSCs) that can then be differentiated into a wide […]

June 13, 2023 - 3 minutesmins - By Jim Cornall

In Depth 13 Jun 2023

Abeta-targeting antibodies pave the way for Alzheimer’s disease vaccines

By Dr. Andrea Pfeifer, CEO of AC Immune SA The clinical success we’ve recently seen with two monoclonal antibodies that target the protein amyloid beta (Abeta) has provided hope for patients, a significant boost to the sector but also a strong validation of the “amyloid hypothesis”: removing Abeta plaques is a valid therapeutic strategy for […]

June 13, 2023 - 7 minutesmins - By External Contributor

AI artificial intelligence dementia alzheimer's

News and Trends 13 Jun 2023

How AI can advance research and treatment of CNS disorders

By Xiao Xu, senior research fellow, Cerevance The combination of large-scale biological datasets and developments in artificial intelligence (AI) has revolutionized our understanding and treatment of central nervous system (CNS) disorders. By leveraging AI’s computational power, researchers have been able to interrogate diverse datasets to provide insights into disease mechanisms, discover novel therapeutic compounds, detect […]

June 13, 2023 - 3 minutesmins - By External Contributor

Best in Biotech 12 Jun 2023

Six advancements in Alzheimer’s research over the past year

The most common cause of dementia, Alzheimer’s disease, is a brain disorder that is characterized by cognitive decline which often manifests itself through memory loss, feelings of disorientation and difficulty making decisions. Alzheimer’s occurs when there is an excessive accumulation of proteins in the brain, a hallmark feature of the disease. These proteins, namely, amyloid […]

June 12, 2023 - 12 minutesmins - By Roohi Mariam Peter

Resources

Categories

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Alzheimer’s

Blood tests for Alzheimer’s: a hit or a miss?

Behind closed doors: The unseen controversies and scandals in Alzheimer’s drug trials

Could a natural sweetener from hydrangeas treat Alzheimer’s disease?

Hope for Alzheimer’s patients after Lilly drug results

Partnership to progress neurodegenerative disorder treatments

FDA approves Alzheimer’s treatment

SandboxAQ launches new division to boost drug development

Alchemab Therapeutics unveils Alzheimer’s candidate

‘Clinical trial in a dish’ for Alzheimer’s disease

Abeta-targeting antibodies pave the way for Alzheimer’s disease vaccines

How AI can advance research and treatment of CNS disorders

Six advancements in Alzheimer’s research over the past year

Subscribe to our newsletter to get the latest biotech news!

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!